mechanism of action of eftilagimod alpha for the treatment of breast cancer
Published 2 years ago • 398 plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
2:55
tacti-002 and tacti-003: eftilagimod alpha for metastatic head and neck squamous cell carcinoma
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
2:54
final update on aipac: eftilagimod alpha plus paclitaxel in patients with metastatic hr her2- bc
-
3:11
aipac: final results of phase iib trial of eftilagimod alpha vs placebo with chemo for hr her2- mbc
-
1:08
the role of immunotherapy in endocrine-refractory luminal breast cancer
-
4:59
phase i insight platform trial: eftilagimod alpha with avelumab in advanced solid tumors
-
2:47
the mechanism of action of immunotherapy for cancer treatment
-
5:50
immunotherapy and breast cancer: how does it work?
-
5:55
how to understand immunotherapy for breast cancer treatment
-
3:35
cancer immunotherapy
-
2:06
immu-132 - a novel antibody-drug conjugate for the treatment of lung cancer
-
1:01
the metastatic breast cancer project
-
6:21
nccn animation for patients: overview of endocrine therapy for metastatic breast cancer
-
1:14
endocrine therapy resistance in er metastatic breast cancer
-
1:53
active breathing coordinator: treatment for left-breast cancer
-
1:10
addressing the mechanism of action for the akt pathway in tnbc
-
1:27
treating er breast cancer patients with endocrine therapy resistance
-
4:37
breast cancer treatment
-
1:31
dr. gwin on the mechanism of action of 𝞪-tea in her2-positive metastatic breast cancer